Ralliant Corporation $RAL Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC cut its holdings in Ralliant Corporation (NYSE:RAL) by 5.3% during the 1st quarter, Holdings Channel.com reports. The fund owned 230,081 shares of the company’s stock after selling 12,819 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Ralliant were worth $9,801,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Twin Capital Management Inc. acquired a new stake in Ralliant during the first quarter valued at approximately $916,000. Principal Financial Group Inc. increased its holdings in shares of Ralliant by 2.0% in the first quarter. Principal Financial Group Inc. now owns 546,560 shares of the company’s stock valued at $22,731,000 after buying an additional 10,592 shares in the last quarter. Fifth Third Bancorp increased its holdings in shares of Ralliant by 3,988.0% in the first quarter. Fifth Third Bancorp now owns 32,132 shares of the company’s stock valued at $1,336,000 after buying an additional 31,346 shares in the last quarter. Moran Wealth Management LLC acquired a new stake in shares of Ralliant during the 1st quarter valued at $227,000. Finally, Counterpoint Mutual Funds LLC acquired a new stake in shares of Ralliant during the 1st quarter valued at $855,000.

Analysts Set New Price Targets

A number of brokerages recently issued reports on RAL. Weiss Ratings restated a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. Truist Financial reiterated a “buy” rating and issued a $68.00 price target (up from $53.00) on shares of Ralliant in a research report on Wednesday, May 13th. Citigroup increased their price target on Ralliant from $70.00 to $81.00 and gave the company a “buy” rating in a research report on Monday, July 13th. TD Cowen boosted their price objective on Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, May 20th. Finally, Zacks Research upgraded Ralliant from a “hold” rating to a “strong-buy” rating in a report on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $73.00.

Ralliant Price Performance

RAL opened at $70.12 on Thursday. The stock has a fifty day moving average of $66.03 and a 200-day moving average of $53.55. The firm has a market capitalization of $7.85 billion and a P/E ratio of -6.41. Ralliant Corporation has a 12-month low of $37.27 and a 12-month high of $75.41. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. The business had revenue of $534.60 million for the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company’s revenue for the quarter was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities analysts forecast that Ralliant Corporation will post 2.64 EPS for the current fiscal year.

Ralliant Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were given a dividend of $0.05 per share. The ex-dividend date was Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is presently -1.83%.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.